{"url_path":"/sec/hrmy/8-k/2026-05-14/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-061237-index.html","accession_number":"0001104659-26-061237","cik":"0001802665","ticker":"HRMY","issuer_name":"Harmony Biosciences Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1802665/0001104659-26-061237-index.html","primary_entity_key":"0001802665","primary_entity_name":"Harmony Biosciences Holdings, Inc."},"word_count":397,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n​\n\nOn May 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 50,381,309 shares of the Company’s common stock were represented in person or by proxy, constituting a quorum. At the Annual Meeting, stockholders voted on the following three proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026.\n\n​\n\nProposal 1. The election of four Class III directors listed below to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Votes For**\n\n**Withheld**\n\n**Broker Non-Votes**\n\n**Geno Germano**\n\n44,963,163\n\n1,524,142\n\n3,894,004\n\n**Troy Ignelzi**\n\n32,813,495\n\n13,673,810\n\n3,894,004\n\n**Ron Philip**\n\n31,826,838\n\n14,660,467\n\n3,894,004\n\n**Andreas Wicki, Ph.D.**\n\n25,114,526\n\n21,372,779\n\n3,894,004\n\n​\n\nBased on the votes set forth above, each of the director nominees was duly elected.\n\n​\n\nProposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\n​\n\n​\n\n​\n\n​\n\n**Votes For**\n\n**Votes Against**\n\n**Abstain**\n\n49,385,510\n\n830,697\n\n165,102\n\n​\n\nBased on the votes set forth above, the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2026, was duly ratified.\n\n​\n\nProposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Vote**\n\n33,249,862\n\n13,042,898\n\n194,545\n\n3,894,004\n\n​\n\nBased on the votes set forth above, the shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n**HARMONY BIOSCIENCES HOLDINGS, INC.**\n\n​\n\n​\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Christian Ulrich\n\n​\n\n​\n\nChristian Ulrich\n\n​\n\n​\n\nEVP and General Counsel\n\n​\n\n​\n\n​"}